Incretin Drugs MDL Judge Denies Plaintiffs’ Motion for Production of Adverse Event Documents

SAN DIEGO — The judge overseeing the federal incretin mimetic drugs multidistrict litigation has denied plaintiffs’ request to compel defendants to produce source documents underlying adverse event reports, finding this information is irrelevant to the issues of preemption and causation.

On Oct. 6, Judge Anthony J. Battaglia of the U.S. District Court for the Southern District of California further ruled that compelling production of these documents would impose an undue burden on defendants.

In this litigation, plaintiffs allege they developed pancreatic cancer after receiving incretin mimetic drugs such as Januvia, Byetta, Janumet and Victoza to treat their diabetes.

Plaintiffs …